Gene therapy to lower eye pressure in glaucoma patients
Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment
This study is exploring a new gene therapy that could help people with glaucoma by improving how fluid drains from the eye, which may lower eye pressure and protect vision, and it will first be tested in lab cells and animals before moving on to humans.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanoscope Technologies, LLC NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project ID | NIH-10695868 on NIH RePORTER |
What this research studies
This research investigates a novel gene therapy approach to treat glaucoma by using engineered mechanosensitive channels to modulate pressure in the eye. The therapy aims to improve drainage of aqueous humor, which is often impaired in glaucoma patients, leading to elevated intraocular pressure (IOP) and potential vision loss. By delivering this therapy via a viral vector, the researchers hope to provide a long-lasting solution that minimizes side effects associated with current treatments. The study will involve testing the effectiveness of this therapy in both cultured cells and animal models before considering human applications.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with glaucoma, particularly those who are elderly or have a family history of the condition.
Not a fit: Patients with other forms of eye disease unrelated to glaucoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option for glaucoma patients, potentially preventing vision loss and improving quality of life.
How similar studies have performed: While gene therapy for glaucoma is a relatively novel approach, preliminary studies have shown promise in similar methodologies, indicating potential for success.
Where this research is happening
Arlington, United States
- Nanoscope Technologies, LLC — Arlington, United States (Active)
Researchers
- Principal investigator: Dibas, Adnan Ismail — Nanoscope Technologies, LLC
- Study coordinator: Dibas, Adnan Ismail
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.